Keywords: genentech, options, exelixis, mek, inhibitor, biotechnology, major

Genentech options Exelixis' MEK inhibitor

Article | 24 March 2008

Biotechnology major Genentech has exercised its option to further develop and commercialize fellow USA-based Exelixis' XL518, a selective inhibitor of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Genentech

Go to company listing